Relationship between erythrocyte GLUT1 function and membrane glycation in type 2 diabetes.

This paper investigates the effect of glycation on glucose transport in erythrocytes. Glucose transporter function, numbers and erythrocyte phosphorylation rates are simultaneously studied using 30 Caucasian patients with diabetes and 30 Caucasian control volunteers (mean +/- SD where P < or = 0.05; age 48 +/- 8 vs.

Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes.

Aims: To examine the inter-relationships of various microvascular pathogenic mechanisms in diabetic patients.

Methods: Patients with diabetes (n = 18) and non-diabetic subjects (n = 18) were studied.

Results: Blood markers of glycaemic control and glycation differed between the two groups (glucose 10.

Effect of bone morphogenetic protein-6 on haemopoietic stem cells and cytokine production in normal human bone marrow stroma.

Normal human bone marrow stroma cells include stem cells for both haemopoietic and osteochondrogenic lineages and express both bone morphogenetic protein (BMP) type I and type II receptors. As a member of the TGF-beta super-family, BMP-6 binds to both BMP type I and type II receptors and is involved in the developmental processes of renal and hepatic systems as well as of human foetal intestine. Also, BMP-6 induces osteoblastic differentiation of pluripotent mesenchymal cells and is an autocrine stimulator of chondrocyte differentiation.

Synthetic cytokines containing interleukin-3 exert potent megakaryopoietic activity.

The shared properties of haematopoietic cytokines and their receptors have enabled the genetically engineered construction of several synthetic cytokines with increased haematopoietic activity and/or more desirable pharmacological characteristics. Thrombocytopenia remains a significant cause of morbidity in cancer patients undergoing allogeneic or autologous bone marrow/blood stem cell transplantation after myeloablative therapy including total body irradiation. Several in vitro, in vivo and preliminary clinical studies have demonstrated the efficacy of synthetic cytokines containing interleukin-3 in accelerating platelet recovery after radiotherapy-induced myelosuppression, enhancing G-CSF-mobilisation of CD34 positive cells for transplantation and increasing the ex-vivo expansion of myeloid and megakaryocytic progenitor cells.